BamSEC and AlphaSense Join Forces
Learn More

China PharmaHub Corp.

Material Contracts Filter

EX-10.17
from 8-K/A 29 pages Services Agreement
12/34/56
EX-10.16
from 8-K/A 28 pages Services Agreement
12/34/56
EX-10.15
from 8-K/A 30 pages Services Agreement
12/34/56
EX-10.14
from 8-K/A 28 pages Services Agreement
12/34/56
EX-10.13
from 8-K/A 10 pages Letter of Intent ( the Application of Glass Microspheres to Treat Cancer ) Background
12/34/56
EX-10.12
from 8-K/A 8 pages Contract No.: Cpcgzxx20101125 China PharmaHub Corp Xiangxue Pharmaceutical Co., Ltd. Cooperation Agreement 1
12/34/56
EX-10.11
from 8-K/A 7 pages Contract No.: Cpcyk20101220 China PharmaHub Corp Chengdu Yunke Pharmaceutical Co., Ltd. Cooperation Agreement 1
12/34/56
EX-10.10
from 8-K/A 8 pages Contract No: Cpcgbd2011-01 China PharmaHub Corp Guangzhou Baidi Biotechnology Co., Ltd. Cooperation Agreement 1
12/34/56
EX-10.9
from 8-K/A 15 pages Exclusive Distributorship Agreement
12/34/56
EX-10.6
from 8-K/A 9 pages R E C I T a L S
12/34/56
EX-10.3
from 8-K/A 77 pages Agreement
12/34/56
EX-10.8
from 8-K/A 3 pages November 15, 2010 Mr. Richard Lui Founder, Chairman and CEO China PharmaHub Corp. 20955 Pathfinder Road, Suite 100 Diamond Bar, Ca 91765 Dear Mr. Lui: Section I. Services to Be Rendered. the Purpose of This Letter Is to Set Forth the Terms and Conditions on Which China PharmaHub Corp. (The "Company")agrees to Engage Stern Investor Relations, Inc. ("Stern Ir") to Render Investor Relations Services. Section 2. Fees. (A) the Company Shall Pay to Stern Ir for Its Services Hereunder a Cash Fee of $10,000 Per Month for the Period Beginning November 15, 2010 and Ending May 31, 2011 Payable in Advance Before the Beginning of Each Month Which Occurs During Such Period (The "Engagement Period")
12/34/56
EX-10.6
from 8-K/A 9 pages “Pursuant to 17 C.F.R. § 240.24b-2, Confidential Incormation (Indicated by [*]) Has Been Omitted From This Document and Has Been Filed Separately With the Securities and Exchange Commission Pursuant to a Confidential Treatment Application Filed With the Commission” Exclusive Distributor Agreement
12/34/56
EX-10.4
from 8-K/A 6 pages Translation Cooperation Agreement Between China PharmaHub Corp and Chengdu Yongkon Pharmacy Co., Ltd. 1
12/34/56
EX-10.3
from 8-K/A 75 pages “Pursuant to 17 C.F.R. § 240.24b-2, Confidential Incormation (Indicated by [*]) Has Been Omitted From This Document and Has Been Filed Separately With the Securities and Exchange Commission Pursuant to a Confidential Treatment Application Filed With the Commission” Agreement
12/34/56
EX-10.2
from 8-K/A 8 pages Exclusive Business Cooperation Agreement
12/34/56
EX-10.1
from 8-K/A 99 pages Merger Agreement
12/34/56
EX-10.1
from 10-Q ~5 pages Cooperation Agreement Background
12/34/56